Skip to main content
Medical Reference · Condition Monograph

Myopathy

근질환

Myopathy is an umbrella term for a variety of diseases in which “the muscle fibers themselves do not work properly,” and long ago it was not clearly distinguished from diseases in which the nerves are the problem, such as neuropathy.

History

Myopathy is an umbrella term for a variety of diseases in which “the muscle fibers themselves do not work properly,” and long ago it was not clearly distinguished from diseases in which the nerves are the problem, such as neuropathy. In the 19th and early 20th centuries, as hereditary muscle diseases such as muscular dystrophy (MD) were clinically defined, the concept of “a disease of the muscle itself” became established, and as muscle biopsy, which examines muscle tissue under a microscope, and electromyography (EMG) developed, the category of myopathy expanded rapidly. Later, as the pattern of elevated muscle enzymes such as creatine kinase (CK) in blood tests became known, it became relatively easy to infer that the cause might lie in the muscle.

From the late 20th century, diseases caused by a single-gene abnormality, such as Duchenne muscular dystrophy (DMD), were confirmed one by one through genetic testing, and in idiopathic inflammatory myopathy (IIM), autoantibodies became important clues that determine diagnosis and prognosis.

Recent research shows that, with the widespread use of next-generation sequencing (NGS), there is a shift from “an era of classifying by symptoms and biopsy alone” to “an era of classifying by looking at genetic, immune, and metabolic mechanisms together,” and it emphasizes the direction in which treatment strategies differ by subtype even within the same diagnosis.

Causes

Myopathy does not have a single cause, and it is easier to understand by broadly dividing the causes into “genetic causes” and “acquired causes.” Genetic causes include cases in which proteins that maintain muscle structure are deficient or defective, as in muscular dystrophy (MD); cases in which the muscle contraction apparatus is abnormal from birth, as in congenital myopathy (CM); cases in which the factories that produce energy do not work properly, as in mitochondrial myopathy (MM); and cases in which there is a defect in the process of handling the fuels (sugar and fat) needed during exercise, as in metabolic myopathy.

Acquired causes include cases in which the immune system attacks the muscles, as in idiopathic inflammatory myopathy (IIM); endocrine myopathy, caused by endocrine abnormalities such as thyroid disease; cases in which drugs such as statins or steroids (glucocorticoids) affect the muscles, as in drug-induced myopathy; muscle injury caused by alcohol, toxic substances, or infection; and cases in which the muscles weaken in the course of a severe systemic illness and its treatment, as in critical illness myopathy (CIM).

Because treatment differs completely depending on the cause, the key is not to draw conclusions from the symptom “my muscles hurt” alone, but to look at the rate of progression and distribution, accompanying symptoms, medications, and family history together.

Genetic Epidemiology

Genetic epidemiology is the perspective that deals with “which genetic changes produce which myopathies, and how those changes are distributed among people.” The genetic causes of myopathy are more diverse than one might think: some diseases develop from an abnormality in a single gene alone (single-gene disorders), while in others, several genes and environmental factors act together. For example, Duchenne muscular dystrophy (DMD) is X-linked, so it occurs mainly in males, and it can first arise from a newly occurring variant (de novo variant) even without a family history.

Limb-girdle muscular dystrophy (LGMD) has a very wide range of causative genes and can be inherited in an autosomal recessive (AR) or autosomal dominant (AD) manner, so even within the same “LGMD,” family history and the pattern of progression differ. Congenital myopathy (CM) and metabolic myopathy also involve many types of genes, and there is a trend in which patients who used to remain “of unknown cause” are increasingly receiving a genetic diagnosis in recent years.

Recent research shows that, thanks to next-generation sequencing (NGS), many genes can be tested at once, raising the diagnostic rate, and the fact that symptoms and complications differ depending on the location of the variant even within the same gene is being defined more precisely.

General Epidemiology

General epidemiology is the area that looks at “how common myopathy is, in which age groups it often begins, and whether there are sex differences.” It is difficult to group all myopathies together and say “the prevalence is such-and-such,” because myopathy is the union of several disease groups. However, among the large categories frequently encountered in clinical practice, idiopathic inflammatory myopathy (IIM), drug-induced myopathy, and endocrine myopathy are important as causes of newly starting muscle weakness in adults.

On the other hand, when progressive muscle weakness appears in children or adolescents, hereditary muscular dystrophy (MD) or congenital myopathy (CM) is suspected first. In older adults, if it progresses slowly with grip strength and knee extension weakening together, specific inflammatory myopathies such as inclusion body myositis (IBM) enter the differential diagnosis.

Recent research emphasizes that, due to the growing older population and advances in diagnostic technology, “there is a tendency for more patients than before to be diagnosed with myopathy and to be classified into more finely subdivided subtypes.”

Pathogenesis

For a muscle to generate force, the contractile proteins inside the muscle cells must be arranged normally, the signal from the nerve must be transmitted through the muscle cell membrane, calcium signals must rise and fall appropriately, and energy (ATP) must be sufficiently supplied. The mechanism of myopathy differs depending on which step of this process breaks down.

In muscular dystrophy (MD), a protein that supports the muscle cell membrane (e.g., dystrophin) is deficient, so the cell membrane is easily damaged with every contraction, and repeated damage leads to inflammation and fibrosis, causing the muscle to gradually waste away. In idiopathic inflammatory myopathy (IIM), immune cells and inflammatory substances attack the muscle fibers, causing the muscles to swell and weaken, and autoantibodies distinguish specific subtypes and can also be linked to involvement of organs such as the lungs and skin. In mitochondrial myopathy (MM) and metabolic myopathy, energy production is insufficient, so the person tires easily during exercise, and in severe cases this can lead to muscle injury (rhabdomyolysis).

Recent research frequently mentions “abnormal calcium regulation,” “oxidative stress,” and “chronic inflammation and fibrosis” as common pathways that influence one another and worsen the disease. Understanding these complex mechanisms is leading to the discovery of new treatment targets.

Symptoms

The most typical symptom of myopathy is muscle weakness, but the way patients describe it varies. It often begins with changes in daily function such as “I'm losing strength,” “stairs are hard,” “it's difficult to raise my arms and work overhead,” or “it's a struggle to get up from a chair.” In particular, proximal weakness around the shoulders and hips is common, so climbing stairs, getting up from sitting, and holding up objects for a long time may become difficult first.

Metabolic myopathy can cause severe fatigue or cramps only during exercise, and sometimes muscle injury (rhabdomyolysis) in which the urine turns cola-colored. Idiopathic inflammatory myopathy (IIM) progresses subacutely, with severe fatigue along with muscle weakness, and may be accompanied by a skin rash (dermatomyositis) or cough and shortness of breath (interstitial lung disease, ILD).

In some hereditary muscular dystrophies, the heart muscle and respiratory muscles weaken as well, which can lead to palpitations, shortness of breath, and breathing problems at night. Because these complications can be life-threatening, regular evaluation of heart and respiratory function is important.

Signs

The important signs on physical examination are the “distribution” and “pattern” of muscle weakness. In myopathy, sensation is usually normal, so the problem often centers on strength and loss of function rather than numbness or reduced sensation. If there is proximal weakness, a movement such as Gowers' sign may be observed, in which the person pushes up on the thighs with the hands when getting up from the floor, and gait features such as a waddling gait or toe walking may appear.

In long-standing progressive muscle disease, muscle atrophy or pseudohypertrophy may be seen. Deep tendon reflexes are often preserved in the early stages, but this can vary depending on the disease. Elevated creatine kinase (CK) is common on blood tests, and a myopathic pattern may appear on electromyography (EMG).

Muscle MRI identifies the pattern of involvement, such as edema (inflammation) or fatty degeneration, to gauge the extent, and helps determine the site for a muscle biopsy if needed. Narrowing down which myopathy it is through the combination of signs is the core of diagnosis.

Screening

The key to “screening” in terms that laypeople can easily understand is to suspect myopathy and get evaluated when a particular pattern of muscle weakness appears. For example, if movements you used to do well, such as climbing stairs, standing up from a chair, or raising your arms over your head to do your hair, become clearly difficult over a few weeks to a few months, testing is needed. If you repeatedly experience unusually severe cramps with exercise, severe muscle pain after exercise, and darkening of the urine, metabolic myopathy or muscle injury caused by drugs or toxins should be considered.

If you are taking medications, checking whether any of them can affect the muscles, such as statins, steroids (glucocorticoids), or certain antiviral drugs, is also part of screening. At medical facilities, basic blood tests check creatine kinase (CK), liver enzymes (AST/ALT), electrolytes, thyroid function, and so on to quickly gauge “whether the muscles are actually being damaged” and “whether there is another cause weakening the muscles.”

Recent research emphasizes an approach of shortening the time to diagnosis with early gene panel testing when a hereditary disease is suspected or the cause is unclear. The earlier the cause is identified, the better it is for establishing an appropriate treatment plan and preventing complications.

Diagnosis

Rather than ending with a single test, it is safer to diagnose myopathy by narrowing down the cause step by step. First, the medical history checks the rate of progression (acute, subacute, chronic), the distribution of weakness (proximal, distal), pain and cramps, family history, exposure to drugs and toxins, and whether there is infection. Next, a physical and neurological examination evaluates the pattern of muscle weakness, gait, contractures, skin findings, and breathing and swallowing problems.

Blood tests check muscle enzymes including creatine kinase (CK), inflammatory markers, thyroid function, and so on, and if idiopathic inflammatory myopathy (IIM) is suspected, myositis-related autoantibodies are evaluated depending on the situation. Electromyography (EMG) and nerve conduction studies (NCS) are important for differentiating “whether it is a muscle problem or a nerve problem.” Muscle MRI or ultrasound identifies the extent of involvement and activity (edema), helping to select the biopsy site.

When the diagnosis is unclear or inflammation, deposits, or structural abnormalities need to be confirmed, a muscle biopsy can be decisive. If a hereditary muscle disease is suspected, the cause is confirmed through genetic testing (especially NGS), and for diseases with possible involvement of the heart or lungs, cardiac testing and respiratory function evaluation are carried out together.

Treatment

Treatment must combine “treatment tailored to the cause” and “treatment that preserves function.” In idiopathic inflammatory myopathy (IIM), steroids (glucocorticoids) and immunosuppressants are the main treatments, and treatments such as intravenous immunoglobulin (IVIG) or biologics may be added depending on the disease subtype and organ involvement. In drug-induced myopathy, adjusting or stopping the causative drug is most important, and in some cases there are forms that persist even after the drug is stopped, such as immune-mediated necrotizing myopathy (IMNM), so specialist evaluation is needed. Endocrine myopathy can improve when hormonal problems such as thyroid problems are corrected.

For hereditary muscular dystrophies and congenital myopathies, fundamental treatment is often limited, but rehabilitation, respiratory and cardiac management, and prevention of complications greatly determine the prognosis. For metabolic myopathy, depending on the type, exercise adjustment, dietary adjustment, and specific supplementation may help, and education on avoiding muscle injury caused by excessive exercise is important.

Recent research shows growing discussion that treatments targeting specific signaling pathways (e.g., JAK inhibition) or targeted immunotherapy may help some patients. Common to all myopathies, physical therapy and exercise prescription, nutritional management, fall prevention, and evaluation of breathing and swallowing form the major pillars of treatment.

Prognosis

Prognosis differs greatly depending on “what type of myopathy it is.” Acquired causes, especially endocrine myopathy and some drug-induced myopathies, can recover relatively well once the cause is corrected. In idiopathic inflammatory myopathy (IIM), daily function can be considerably restored when the response to treatment is good, but the prognosis can differ if diagnosis is delayed or there are complications such as lung involvement (interstitial lung disease, ILD).

Hereditary muscular dystrophy (MD) usually progresses slowly, and not only the decline in walking ability but also whether the respiratory muscles and heart are involved determines the long-term prognosis. Mitochondrial myopathy (MM) and metabolic myopathy show large fluctuations in symptoms and can worsen rapidly in situations such as infection, overexertion, or fasting, so lifestyle management is important.

Recent research emphasizes “strategies to predict prognosis more specifically and monitor for complications early” thanks to more precise genetic diagnosis, and in some hereditary diseases, the prognostic outlook is changing as gene-targeted therapies advance.

Prevention

Many myopathies involve genetic factors or immune abnormalities, so “complete prevention of onset” is often difficult. Nevertheless, prevention that reduces worsening and complications is possible. For drug-induced myopathy, it helps for people taking at-risk medications to recognize warning signs such as muscle pain, muscle weakness, and changes in urine color early, and to avoid excessive exercise, dehydration, and drug interactions. For metabolic myopathy, strenuous exercise, dehydration, and prolonged fasting can trigger muscle injury (rhabdomyolysis), so managing lifestyle habits is important.

In idiopathic inflammatory myopathy (IIM), infection can provoke worsening, so vaccination, hand hygiene, and early treatment of infections are important, and strategies to prevent infections associated with immunosuppression during treatment are needed. In hereditary muscle diseases, genetic counseling can be helpful in relation to family planning, and after diagnosis, regular checkups to detect respiratory and cardiac complications early constitute secondary prevention.

Ultimately, “prevention” of myopathy should focus not simply on preventing the disease but on avoiding aggravating factors and managing complications in advance so that function is maintained for as long as possible.

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.